In general, bombesin-based tracers could take a complementary role to PSMA inhibitors for prostate cancers and, furthermore, might also be applicable for the imaging of breast cancer and gastrointestinal stromal tumors. This evidence concerns the gene FOLH1 and prostate cancer.